{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.5","upperLimit":"38.6","value":"25.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"The proportion of patients who experience grade 2 or higher xerostomia or start amifostine and/or pilocarpine within 90 days of the start of radiation therapy. A proportion less than or equal to 51% would be considered acceptable based on the results of the U.S. Bioscience phase III amifostine trial (this trial preceded FDAAA requirements).","dispersionType":"95% Confidence Interval","groups":[{"description":"Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.","id":"OG000","title":"Surgery + Transfer + Radiation"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started RT","reportingStatus":"POSTED","timeFrame":"From start of treatment to 90 days","title":"Percentage of Patients With Acute Xerostomia","type":"SECONDARY","unitOfMeasure":"percentage of participants"}